Age, comorbidity, treatment decision and prognosis in lung cancer
Age, comorbidity, treatment decision and prognosis in lung cancer
复制标题
DOI：
10.1093/ageing/afn226
复制
发表时间：
2008-11-01
期刊：
影响因子：
6.7
通讯作者：
Gonzalez Martin, Isidro Jesus
中科院分区：
文献类型：
--
作者：
Gullon Blanco, Jose Antonio;Toste, Isabel Suarez;Gonzalez Martin, Isidro Jesus
在这项研究中，年龄和合并症在晚期NSCLC的治疗决策中起着重要作用。两项人群研究[9，10]发现，在晚期，在60-79岁的年龄组中，治疗有症状的患者占34%-40%，80岁或以上的患者增加到52%-65%，而< 60岁的患者为19%-20%。在这些系列中，合并症也影响治疗选择，但不如年龄重要。在我们的病例中，这两个变量都与只接受BSC的可能性相关，尽管这种相关性随着年龄的增长而增强。
DiscussionIn this study, age and comorbidity played an important role in treatment decisions in advanced NSCLC. Two population studies [9, 10] found that in advanced stages, in the age group of 60–79 years, treatment was symptomatic in∼ 34–40% of patients increasing to 52–65% in those aged 80 years or older as compared with 19–20% in patients aged< 60 years. In these series, comorbidity also influenced therapeutic choice but was less important than age. In our case both variables were correlated with the likelihood of receiving only BSC although the association was stronger with age.